ArticleProceedings of the National Academy of Sciences of the United States of America2018
Radioactive (
Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Nanotechnology integration in oncology for advanced nanoparticle based strategies in targeted cancer diagnosis and treatment.Discover nano · 2026Review
- In situ radiochemical doping of functionalized inorganic nanoplatforms for theranostic applications: a paradigm shift in nanooncology.Journal of nanobiotechnology · 2025Review
- Engineered upconversion nanoparticles for breast cancer theranostics.Theranostics · 2025Review
- Radiation nanomedicines for cancer treatment: a scientific journey and view of the landscape.EJNMMI radiopharmacy and chemistry · 2024Review
- Recent Advances on Affibody- and DARPin-Conjugated Nanomaterials in Cancer Therapy.International journal of molecular sciences · 2023Review
- Prospects for the Use of Metal-Based Nanoparticles as Adjuvants for Local Cancer Immunotherapy.Pharmaceutics · 2023Review
- Theranostics in breast cancer.Frontiers in nuclear medicine · 2023Review
- Synergistic Effect of the Combined Action of Targeted and Photodynamic Therapy on HER2-Positive Breast Cancer.Doklady. Biochemistry and biophysics · 2022Article
- Bioimaging with Upconversion Nanoparticles.Advanced photonics research · 2022Article
- Protein scaffolds: antibody alternatives for cancer diagnosis and therapy.RSC chemical biology · 2022Review
- Review
- Nanoparticles in Clinical Translation for Cancer Therapy.International journal of molecular sciences · 2022Review
- Natural and Designed Toxins for Precise Therapy: Modern Approaches in Experimental Oncology.International journal of molecular sciences · 2021Review
- The Use of Upconversion Nanoparticles in Prostate Cancer Photodynamic Therapy.Life (Basel, Switzerland) · 2021Review
- UCNP-based Photoluminescent Nanomedicines for Targeted Imaging and Theranostics of Cancer.Molecules (Basel, Switzerland) · 2020Article
- Multifunctional Complexes Based on Photoluminescent Upconversion Nanoparticles for Theranostics of the HER2-Positive Tumors.Doklady. Biochemistry and biophysics · 2020Article
- Article
- Recent Advances on Rare Earth Upconversion Nanomaterials for Combined Tumor Near-Infrared Photoimmunotherapy.Frontiers in chemistry · 2020Review
- Functionalized Upconversion Nanoparticles for Targeted Labelling of Bladder Cancer Cells.Biomolecules · 2019Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report combined therapy using upconversion nanoparticles (UCNP) coupled to two therapeutic agents: beta-emitting radionuclide yttrium-90 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.